Clinical Trial Update: EGCG for the Prevention and Treatment of TIPN [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is recruiting to evaluate epigallocatechin gallate (EGCG) for prevention and treatment of chemotherapy-induced peripheral neuropathy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Peripheral Neuropathy

Drugs mentioned

• EGCG (epigallocatechin gallate)

Snippet

Sponsor: Han Xi Zhao | Conditions: Chemotherapy-induced Peripheral Neuropathy | Phase 1, Phase 2 | Status: RECRUITING